Sanofi investigated over epilepsy drug linked to birth defects
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 4% to two-week high after Trump says deal with Iran 'over'
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Sanofi (SNY) Reports Q4 Revenues of EUR9.61B
February 6, 2020 8:05 AM ESTSanofi (NASDAQ: SNY) reported Q4 EPS of EUR1.34. Revenue for the quarter came in at EUR9.61 billion.
Sanofi Chief Executive Officer, Paul Hudson, commented:
"I am encouraged by the fourth quarter results which position Sanofi to deliver on our new strategic priorities.... More
